IXICO releases financial results for the year ended 30 Sept 2021
IXICO plc (AIM: IXI) announces its results for the year ended 30 September 2021, delivering a year of significant growth in profitability despite notable headwinds to trading. HighlightsFinancial EBITDA* of £1. 7 million; 34% increase on prior year (2020: £1.READ MORE
AD/PD 2021 Poster - Automatic segmentation using deep learning for the hippocampusREAD MORE
“We love a challenge.” - Meet Romina Oxborough, our Senior Vice President of Operations
Romina Oxborough recently joined the IXICO team as Senior Vice President of Operations, bringing a wealth of experience in developing strategic services underpinned by operational delivery. We spoke to Romina about her experience so far at IXICO and the main thing that gets her out of bed in the morning. Hi Romina.READ MORE
Associate Director Project Management (Clinical Trial)READ MORE
We can work with you on the selection and use of medical imaging and digital biomarkers for your drug development programs, directly and as part of collaborative consortia.
We are experts in the definition and delivery of early phase clinical development, where rigorous patient safety runs hand-in-hand with flexibility around trial design and data analytics.
Our global network of over 2,000 imaging centers across 75 countries ensures large-scale trials can be set up quickly and efficiently, while our custom TrialTracker platform delivers highly reliable, regulatory compliant data.
We understand the challenges of extended longitudinal studies. We support you to monitor patient safety and drug utilization for ongoing optimization of patient pathways post-marketing.
IXICO is a leading provider at the forefront of advancing Alzheimer's disease (AD) imaging biomarkers, having focused on AD clinical research since 2007. We have conducted over 40 Alzheimer's disease studies, bringing together deep therapeutic expertise, breakthrough AI analytics and operational agility to deliver extraordinary clinical insights.Read more
IXICO is the leading company for Huntington's disease (HD) specialist imaging. Our neuroscience expertise enables global, regulatory compliant imaging and digital biomarker analytical services for clinical development. We are a trusted imaging provider and preferred supplier for pharma and biotech, with IXICO providing advanced imaging analytics for 11 HD trials.Read more
IXICO first supported a clinical study for PD in 2016 and continue to invest in our technological solutions to support clinical trials in this area. PD is the second most common neurodegenerative disease, after Alzheimer’s disease. An estimated 7 to 10 million people worldwide are living with PD.Read more
We have been involved in MS since 2015 through our Assessa PML collaboration with big pharma. Multiple Sclerosis is a condition that affects the brain and spinal cord. It is the most common autoimmune disorder of the central nervous system, affecting around 2.3 million people globally as of 2015.Read more
Progressive Supranuclear Palsy (PSP) is a Parkinsonian neurological rare condition caused by the premature loss of nerve cells in certain parts of the brain, which leads to difficulties with balance, movement, vision, speech and swallowing. IXICO has supported clinical trials in this area since 2015, providing advanced analytics for 5 clinical trials across 230 global sites.Read more
IXICO specialises in data collection, optimisation, and analytics of rare neurological disorders, including but not limited to Huntington's Disease (HD), Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA), and Spinocerebellar Ataxia (SCA).Read more